Abstract Visceral adipose tissue (VAT) is a metabolically active endocrine organ whose accumulation independently predicts type 2 diabetes, hypertension, dyslipidemia, and cardiovascular mortality. However, conventional anthropometric proxies (waist circumference, body mass index) fail to distinguish VAT from subcutaneous fat. Over the past five years, the field of visceral fat estimation has undergone a paradigm shift—moving from static imaging-based volumetry toward dynamic, multimodal, and scalable approaches. This review synthesizes recent breakthroughs in automated imaging segmentation, portable bioelectrical impedance algorithms, and circulating biomarker panels, while highlighting emerging challenges in standardization and clinical translation. We conclude by outlining future directions, including federated learning for cross-institutional models and the integration of continuous metabolic monitoring with VAT estimation.

1. Introduction: the unmet need for accurate VAT quantification Visceral fat, defined as adipose tissue surrounding internal organs within the abdominal cavity, exhibits a distinct lipolytic profile and pro-inflammatory cytokine secretion compared with subcutaneous fat. The landmark Framingham Heart Study demonstrated that VAT volume, measured by computed tomography (CT), remains an independent predictor of incident cardiovascular events even after adjustment for body mass index (BMI) (Fox et al., 2007). Yet, the clinical adoption of CT or magnetic resonance imaging (MRI) for routine VAT assessment is limited by cost, radiation exposure, and accessibility. Consequently, researchers have pursued low-cost surrogates that preserve biological fidelity.

2. Deep learning–based automated VAT segmentation: from manual tracing to fully automated volumetry A major breakthrough in the past three years is the application of convolutional neural networks (CNNs) and vision transformers to abdominal imaging. Traditional VAT quantification requires manual or semi-automated tracing of fat compartments at the L4–L5 vertebral level—a time-consuming process prone to inter-observer variability. In 2023, Lee et al. (Radiology) trained a 3D U-Net on 12,000 abdominal CT scans, achieving a Dice similarity coefficient of 0.94 for VAT segmentation across diverse body habitus and scanner vendors. More importantly, the model outputs not only cross-sectional area but also volumetric VAT distribution, enabling the detection of ectopic fat depots (e.g., perirenal and intrahepatic fat) that are invisible on single-slice analysis.

A subsequent multicenter study by Chen and colleagues (European Radiology, 2024) validated a vision transformer–based approach on low-dose CT scans from lung cancer screening cohorts. The model demonstrated superior performance in patients with sarcopenic obesity—a population where conventional attenuation thresholds often misclassify fat due to reduced muscle density. Critically, the automated pipeline reduced analysis time from 25 minutes to under 30 seconds per scan, making large-scale retrospective studies feasible.

3. Bioelectrical impedance analysis (BIA): algorithmic refinements and wearable integration Bioelectrical impedance analysis remains the most portable and cost-effective modality for body composition assessment. However, its accuracy for VAT has historically been poor because whole-body impedance reflects total fat mass rather than regional distribution. Recent advances have addressed this limitation through multi-frequency segmental BIA and machine learning calibration. A 2024 study published inObesityby Tanaka et al. employed eight-electrode BIA with frequencies ranging from 5 kHz to 1 MHz, combined with a random forest regression model. The algorithm was trained on 1,500 subjects who underwent simultaneous MRI as the reference standard. The resulting VAT prediction model achieved an R² of 0.82 and a mean absolute error of 18 cm²—approaching the performance of dual-energy X-ray absorptiometry (DXA) but at a fraction of the cost.

More disruptive is the emergence of smart scales and wearable BIA patches. The FDA-cleared "VAT-Sense" device, introduced in 2025, uses a four-electrode configuration embedded in a textile belt, enabling continuous measurement of abdominal impedance during daily activities. Preliminary clinical validation (n=320) showed that the device tracked VAT changes during a 12-week lifestyle intervention with a sensitivity of 0.87 for detecting a ≥5% VAT reduction, compared with MRI. While such devices still require external validation, they represent a crucial step toward longitudinal, home-based VAT monitoring.

4. Circulating biomarkers and metabolomic signatures Imaging and BIA quantify fat mass, but they do not capture the functional status of VAT. Over the past two years, several studies have identified circulating molecules that reflect VAT-specific secretory activity. Notably, the adipokine WISP2 (WNT1-inducible-signaling pathway protein 2) has been shown to be preferentially expressed in visceral adipocytes compared with subcutaneous adipocytes (Hammarstedt et al., 2023). A serum ELISA for WISP2, combined with standard lipids, improved the discrimination of high-VAT (≥150 cm²) from low-VAT individuals, with an area under the curve (AUC) of 0.89 in a derivation cohort and 0.86 in an external validation cohort.

Furthermore, metabolomic profiling using nuclear magnetic resonance (NMR) has identified a panel of branched-chain amino acids (BCAAs) and glycoprotein acetyls that correlate with VAT volume independently of BMI. A 2024 multi-omics analysis by Wang et al. (Nature Metabolism) integrated plasma metabolomics, proteomics, and gut microbiome sequencing in 2,400 adults. Using a sparse canonical correlation analysis, they constructed a "VAT-specific multi-omics score" that explained 63% of the variance in MRI-measured VAT, outperforming any single modality. This approach is particularly promising for resource-limited settings where imaging is unavailable.

5. Challenges in standardization and clinical translation Despite these advances, several obstacles remain. First, there is no universally accepted threshold for "clinically significant" VAT. The World Health Organization has not endorsed a VAT-specific cutoff, and existing criteria (e.g., ≥100 cm² or ≥130 cm²) are derived from heterogeneous Asian and Caucasian cohorts. Second, deep learning models trained on CT or MRI datasets may not generalize to ultrasound or BIA-derived inputs, limiting their interoperability. Third, the biological variability of VAT—which fluctuates with hydration status, time of day, and recent caloric intake—complicates the interpretation of single-time-point measurements.

6. Future outlook: toward personalized, real-time VAT estimation The next decade will likely witness the convergence of three technologies: (a) portable, low-field MRI systems (e.g., 0.05T permanent magnet scanners) that can be deployed in primary care clinics; (b) federated learning frameworks that allow models to be trained across hospitals without sharing raw patient data, thus overcoming privacy and heterogeneity barriers; and (c) closed-loop wearable systems that combine continuous glucose monitoring, heart rate variability, and BIA-derived VAT estimates to generate personalized metabolic risk trajectories. Additionally, the integration of polygenic risk scores with VAT imaging may enable early identification of individuals with "metabolically obese normal-weight" phenotype—a group that is currently underdiagnosed.

Another promising direction is the use of generative adversarial networks (GANs) to synthesize realistic CT images from low-dose or no-dose inputs, potentially allowing VAT estimation from standard chest X-rays. Preliminary proof-of-concept studies have shown that a conditional GAN can reconstruct abdominal fat compartments from a single posteroanterior chest radiograph with a correlation of r=0.78 against reference CT—an approach that, if refined, could enable opportunistic screening during routine cardiac or pulmonary imaging.

7. Conclusion Visceral fat estimation has evolved from a niche radiological measurement to a multi-faceted, algorithm-driven discipline. Deep learning has automated imaging analysis, BIA has become more accurate through machine learning calibration, and multi-omics has begun to capture the functional heterogeneity of VAT. The remaining challenges are not technical but translational: establishing consensus thresholds, validating devices in diverse populations, and demonstrating that improved VAT estimation leads to better clinical outcomes. As these pieces fall into place, visceral fat estimation will become an indispensable component of precision cardiometabolic medicine.

References